MicroRNA-targeted nanoparticle delivery systems for cancer therapy: current status and future prospects.

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-15 DOI:10.1080/17435889.2025.2492542

Yang Lou, Yutian Wang, Juan Lu, Xi Chen

{"title":"MicroRNA-targeted nanoparticle delivery systems for cancer therapy: current status and future prospects.","authors":"Yang Lou, Yutian Wang, Juan Lu, Xi Chen","doi":"10.1080/17435889.2025.2492542","DOIUrl":null,"url":null,"abstract":"<p><p>Recently, the regulatory effects of microRNAs (miRNAs) on gene expression have been exploited for applications in the diagnosis and treatment of cancer, neurological diseases, and cardiovascular diseases. However, the susceptibility of miRNAs to degradation during somatic circulation and the challenges associated with their delivery to target tissues and cells have limited the clinical application of miRNAs. For application in tumor therapy, it is essential for miRNAs to specifically target cancer cells. Therefore, various novel miRNA delivery systems that protect miRNA against the activity of serum nuclease and deliver miRNA to target cells have been developed and optimized. This review introduces the passive and active targeting strategies of nanoparticles, summarizes the recent progress of miRNA nanocarriers with tumor-targeting ability, and discusses various nanoparticle delivery systems and their antitumor applications. Additionally, this review focuses on the translational challenges and potential strategies for advancing miRNA-based therapies into the clinic.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1181-1194"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068351/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2025.2492542","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/15 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Recently, the regulatory effects of microRNAs (miRNAs) on gene expression have been exploited for applications in the diagnosis and treatment of cancer, neurological diseases, and cardiovascular diseases. However, the susceptibility of miRNAs to degradation during somatic circulation and the challenges associated with their delivery to target tissues and cells have limited the clinical application of miRNAs. For application in tumor therapy, it is essential for miRNAs to specifically target cancer cells. Therefore, various novel miRNA delivery systems that protect miRNA against the activity of serum nuclease and deliver miRNA to target cells have been developed and optimized. This review introduces the passive and active targeting strategies of nanoparticles, summarizes the recent progress of miRNA nanocarriers with tumor-targeting ability, and discusses various nanoparticle delivery systems and their antitumor applications. Additionally, this review focuses on the translational challenges and potential strategies for advancing miRNA-based therapies into the clinic.

查看原文本刊更多论文

用于癌症治疗的微rna靶向纳米颗粒递送系统：现状和未来展望。

近年来，microRNAs （miRNAs）对基因表达的调控作用已被开发用于癌症、神经系统疾病和心血管疾病的诊断和治疗。然而，mirna在体细胞循环过程中对降解的易感性以及它们递送到靶组织和细胞的挑战限制了mirna的临床应用。为了在肿瘤治疗中应用，mirna必须特异性靶向癌细胞。因此，各种新的miRNA传递系统被开发和优化，以保护miRNA不受血清核酸酶活性的影响，并将miRNA传递到靶细胞。本文介绍了纳米颗粒的被动靶向和主动靶向策略，综述了具有肿瘤靶向能力的miRNA纳米载体的最新进展，并讨论了各种纳米颗粒递送系统及其抗肿瘤应用。此外，本综述着重于将基于mirna的疗法推进到临床的转化挑战和潜在策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量